Please assess the completion status of the following clinical trial:

Trial Title: Metabolic Response to Infliximab in Pediatric Ulcerative Colitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female children between the ages of six and eighteen years of age~* Endoscopic or histologic evidence of ulcerative colitis~* Active ulcerative colitis determined by primary pediatric gastroenterologist to require anti-tumor necrosis factor-alpha antibody (infliximab) therapy~* Colitis symptom score ≥2~* Screening laboratory tests that meet the following criteria (obtained within 4 weeks of enrollment):~  1. Hemoglobin \>8.0 g/dL~ 2. White blood cell count \>3.5 x 109/L~ 3. Neutrophils \>1.5 x 109/L~ 4. Platelets \>100 x 109/L~ 5. Aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase levels within 3 times the upper limit of normal.~ 6. PPD skin test with skin induration \<5 mm.~ 7. Signed written consent from the parent/legal guardian and assent from the child to be obtained prior to enrollment.~Exclusion Criteria:~* Female subjects who are pregnant, nursing, or planning pregnancy.~* Concomitant diagnosis or history of congestive heart failure.~* Serious infection in the 3 months prior to enrollment.~* History of prior or current active or latent tuberculosis.~* Immune deficiency syndrome, including documented human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS).~* History of systemic lupus erythematosus.~* A transplanted organ.~* Known malignancy or history of malignancy within 5 years of enrollment.~* History of demyelinating disease.~* History of substance abuse.~* History of diabetes mellitus.~* Poor tolerability of venipuncture or lack of venous access during the study period.~* A live virus vaccination within 3 months of enrollment.~* Prior history of infliximab infusion or any other therapeutic agent targeted at reducing tumor necrosis factor-alpha (TNF-alpha).~* Hypersensitivity to any murine proteins or other component of the product.~* Inability to comply with study procedures

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Infliximab (Type: OTHER): Subjects on infliximab

Based on this trial design, predict the completion outcome and termination type (if applicable).